Andrea Muranyi
Overview
Explore the profile of Andrea Muranyi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
561
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Yoon H, Shi Q, Heying E, Muranyi A, Bredno J, Ough F, et al.
Clin Cancer Res
. 2018 Oct;
25(1):125-133.
PMID: 30301825
Purpose: Colorectal cancers with deficient DNA mismatch repair (dMMR) are presumed to uniformly have dense lymphocytic infiltration that underlies their favorable prognosis and is critical to their responsiveness to immunotherapy,...
12.
Kendrick S, Muranyi A, Gokhale V, Hurley L, Rimsza L
J Med Chem
. 2017 Jun;
60(15):6587-6597.
PMID: 28605593
Secondary DNA structures are uniquely poised as therapeutic targets due to their molecular switch function in turning gene expression on or off and scaffold-like properties for protein and small molecule...
13.
Ghosh P, Tie J, Muranyi A, Singh S, Brunhoeber P, Leith K, et al.
Clin Cancer Res
. 2016 Apr;
22(14):3488-98.
PMID: 27029492
Purpose: Prognostic markers that identify patients with stage II colon cancers who are at the risk of recurrence are essential to personalize therapy. We evaluated the potential of GIV/Girdin as...
14.
Kendrick S, Redd L, Muranyi A, Henricksen L, Stanislaw S, Smith L, et al.
Hum Pathol
. 2014 Aug;
45(10):2144-53.
PMID: 25090918
Patients with aggressive, BCL2 protein-positive (+) diffuse large B-cell lymphoma (DLBCL) often experience rapid disease progression that is refractory to standard therapy. However, there is potential for false-negative staining of...
15.
Lopez-Sanchez I, Dunkel Y, Roh Y, Mittal Y, De Minicis S, Muranyi A, et al.
Nat Commun
. 2014 Jul;
5:4451.
PMID: 25043713
Progressive liver fibrosis is characterized by the deposition of collagen by activated hepatic stellate cells (HSCs). Activation of HSCs is a multiple receptor-driven process in which profibrotic signals are enhanced...
16.
Day F, Muranyi A, Singh S, Shanmugam K, Williams D, Byrne D, et al.
Target Oncol
. 2014 May;
10(1):99-109.
PMID: 24859797
The B-type Raf kinase (BRAF) V600E mutation is a well-established biomarker for poor prognosis in metastatic colorectal cancer (mCRC) and is a highly attractive drug target. A barrier to the...
17.
Gehrie E, Muranyi A, Walk E, Young P
Arch Pathol Lab Med
. 2014 Jan;
138(2):155.
PMID: 24476512
No abstract available.
18.
Sinicrope F, Smyrk T, Tougeron D, Thibodeau S, Singh S, Muranyi A, et al.
Cancer
. 2013 May;
119(15):2765-70.
PMID: 23657789
Background: A point mutation (V600E) in the BRAF oncogene is a prognostic biomarker and may predict for nonresponse to anti-EGFR antibody therapy in patients with colorectal carcinoma. BRAFV600E mutations are...
19.
Webb J, Muranyi A, Pugh C, Ratcliffe P, Coleman M
Biochem J
. 2009 Feb;
420(2):327-33.
PMID: 19245366
The asparaginyl hydroxylase FIH [factor inhibiting HIF (hypoxia-inducible factor)] was first identified as a protein that inhibits transcriptional activation by HIF, through hydroxylation of an asparagine residue in the CAD...
20.
Muranyi A, Derkach D, Erdodi F, Kiss A, Ito M, Hartshorne D
FEBS Lett
. 2005 Nov;
579(29):6611-5.
PMID: 16297917
Major sites for Rho-kinase on the myosin phosphatase target subunit (MYPT1) are Thr695 and Thr850. Phosphorylation of Thr695 inhibits phosphatase activity but the role of phosphorylation at Thr850 is not...